Paper · 39215014

AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer.

Ouyang B and 19 others. Nat Commun, 2024. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer. Papers, record 39215014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39215014

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer.; PubMed
Journal: Nat Commun; PubMed
Year: 2024; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39215014/; PubMed
DOI: https://doi.org/10.1038/s41467-024-51980-9; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11364624/; PubMed
The journal: https://conductscience.org/library/journal-index/101528555; PubMed
Citations, by iCite: 41; iCite
Relative citation ratio, by iCite: 5.44, provisional; iCite
Revised in PubMed: 2026-03-17; PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Ouyang B	Boshu	https://orcid.org/0000-0002-0934-434X
2	Shan C	Caihua
3	Shen S	Shun
4	Dai X	Xinnan
5	Chen Q	Qingwang
6	Su X	Xiaomin
7	Cao Y	Yongbin
8	Qin X	Xifeng
9	He Y	Ying
10	Wang S	Siyu

1 to 10 of 20Source PubMed

See all 20 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Triple Negative Breast Neoplasms	Major topic
Pyroptosis	Major topic
Drug Discovery	Major topic
Humans
Female
Animals
Mitoxantrone
Xanthones
Cell Line, Tumor
Antineoplastic Agents
Mice
Artificial Intelligence
Data Mining
Neural Networks, Computer

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
82172073, 51933002, 8217070298	National Natural Science Foundation of China (National Science Foundation of China)			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References68

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	30,279,003	Refining Early Antitumoral Drug Development.	Trends Pharmacol Sci	2018	https://conductscience.org/library/papers/30279003	PubMed
2	34,975,326	Integrative analysis of the molecular mechanisms, immunological features and immunotherapy response of ferroptosis regulators across 33 cancer types.	Int J Biol Sci	2022	https://conductscience.org/library/papers/34975326	PubMed
3	32,254,586	Erythrocyte-platelet hybrid membranes coating polypyrrol nanoparticles for enhanced delivery and photothermal therapy.	J Mater Chem B	2018	https://conductscience.org/library/papers/32254586	PubMed
4	35,637,317	Phenotypic drug discovery: recent successes, lessons learned and new directions.	Nat Rev Drug Discov	2022	https://conductscience.org/library/papers/35637317	PubMed
5	35,713,468	Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.	Chem Soc Rev	2022	https://conductscience.org/library/papers/35713468	PubMed
6	31,106,366	SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules.	Nucleic Acids Res	2019	https://conductscience.org/library/papers/31106366	PubMed
7	33,201,252	BCL2L13: physiological and pathological meanings.	Cell Mol Life Sci	2021	https://conductscience.org/library/papers/33201252	PubMed
8	11,262,395	Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension.	J Biol Chem	2001	https://conductscience.org/library/papers/11262395	PubMed
9	27,626,769	Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.	Adv Mater	2016	https://conductscience.org/library/papers/27626769	PubMed
10	35,288,674	Pyroptosis and pyroptosis-inducing cancer drugs.	Acta Pharmacol Sin	2022	https://conductscience.org/library/papers/35288674	PubMed

1 to 10 of 68

See all 68 references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMID	Title	Journal	Year	In Papers	Source
42,866,318	Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer.	Front Oncol	2026	https://conductscience.org/library/papers/42866318	PubMed
42,662,069	Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.	Front Cell Dev Biol	2026	https://conductscience.org/library/papers/42662069	PubMed
42,423,852	The role of artificial intelligence in precision medicine for breast cancer.	Discov Oncol	2026	https://conductscience.org/library/papers/42423852	PubMed
42,162,002	AI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework.	NPJ Genom Med	2026	https://conductscience.org/library/papers/42162002	PubMed
42,023,218	Integrating bulk, single-cell, and spatial transcriptomics to identify a novel pyroptosis-related gene signature for predicting prognosis and tumor immune landscape in triple-negative breast cancer.	Front Immunol	2026	https://conductscience.org/library/papers/42023218	PubMed
41,844,622	Structural evolution of carbon frameworks realizes in vitro interfacial transport in metabolically reprogrammed senescent cells for senolysis.	Nat Commun	2026	https://conductscience.org/library/papers/41844622	PubMed
41,836,157	Recent Advances and Emerging Directions in Machine Learning-Based Breast Cancer Drug Discovery: A Comprehensive Review.	Breast Cancer (Dove Med Press)	2026	https://conductscience.org/library/papers/41836157	PubMed
41,820,292	Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.	Cell Death Discov	2026	https://conductscience.org/library/papers/41820292	PubMed
41,752,408	Actinolactomycin from Streptomyces sp. CB00271: Isolation, Identification, and Potent Anti-Triple-Negative Breast Cancer.	Molecules	2026	https://conductscience.org/library/papers/41752408	PubMed
41,648,057	Traditional Chinese Medicine Modernization in Diagnosis and Treatment: Utilizing Artificial Intelligence and Nanotechnology.	MedComm (2020)	2026	https://conductscience.org/library/papers/41648057	PubMed

1 to 10 of 23

See all 23 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39215014

GET https://conductscience.org/api/papers/v1/39215014/references?page=2

API reference For AI assistants